Newly launched Ariceum Therapeutics GmbH is preparing to enter the clinic with a radioligand candidate originally developed in parallel with Novartis AG’s Lutathera, which it hopes will one day follow to market with added potency.
Ariceum Hopes To One-Up Novartis Drug With Potent Radiopharmaceutical Focus
Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.
